Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q1 2023 · 10-Q
Revenue$144.77M$144.77M+72.9% vs Q1 2022 Net Income-$17.43M-$17.43MN/M vs Q1 2022 EPS Diluted-$0.51-$0.51N/M vs Q1 2022 Gross Profit$77,402,000+59.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flow$27,671,000N/M Free Cash Flowderived$27,495,000N/M Margins · derivedGross margin53.5%−4.4 pt vs Q1 2022
Operating margin17.0%+29.0 pt vs Q1 2022
Net margin-12.0%+3.6 pt vs Q1 2022
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end